Amgen Inc. $AMGN Shares Sold by AMF Tjanstepension AB

AMF Tjanstepension AB trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 54.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,846 shares of the medical research company’s stock after selling 85,271 shares during the period. AMF Tjanstepension AB’s holdings in Amgen were worth $19,993,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new position in Amgen during the second quarter worth about $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen in the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute bought a new position in shares of Amgen during the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC boosted its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares in the last quarter. Finally, Nvwm LLC grew its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after purchasing an additional 134 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.7%

NASDAQ:AMGN opened at $344.75 on Friday. The business’s fifty day moving average price is $332.07 and its 200 day moving average price is $307.61. The firm has a market capitalization of $185.64 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 3.07 and a beta of 0.45. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $349.98.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is 73.57%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Wall Street Analysts Forecast Growth

AMGN has been the subject of several recent research reports. Morgan Stanley cut their target price on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Wall Street Zen raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. Argus lifted their target price on Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Guggenheim boosted their target price on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $339.24.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.